|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:ATCCode
|
gptkb:L01XX43
|
|
gptkbp:bioavailability
|
31.8%
|
|
gptkbp:brand
|
gptkb:Erivedge
|
|
gptkbp:CASNumber
|
879085-55-9
|
|
gptkbp:drugClass
|
Hedgehog pathway inhibitor
|
|
gptkbp:eliminationHalfLife
|
4 days
|
|
gptkbp:hasFirstInClass
|
yes
|
|
gptkbp:hasInChIKey
|
YMGUEVCWXUQGLM-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C17H19N3O3S
|
|
gptkbp:hasOrphanDrugStatus
|
yes
|
|
gptkbp:hasPatentExpiry
|
2028
|
|
gptkbp:hasSMILES
|
CS(=O)(=O)C1=CC(=C(C=C1)Cl)NC(=O)C2=CC(=C(C=C2)Cl)C3=CC=CC=N3
|
|
gptkbp:hasUNII
|
6HG8UB2MUY
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL31808
|
|
gptkbp:indication
|
treatment of basal cell carcinoma
|
|
gptkbp:IUPACName
|
2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Genentech
|
|
gptkbp:mechanismOfAction
|
Smoothened antagonist
|
|
gptkbp:molecularWeight
|
345.42
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL31808
DB08816
24776440
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fatigue
weight loss
alopecia
dysgeusia
muscle spasms
|
|
gptkbp:status
|
approved
|
|
gptkbp:synonym
|
gptkb:GDC-0449
Vismodegib
|
|
gptkbp:target
|
gptkb:Smoothened_receptor
|
|
gptkbp:therapeuticArea
|
oncology
|
|
gptkbp:bfsParent
|
gptkb:myrcene
|
|
gptkbp:bfsLayer
|
6
|